Evidence map›Paper›PMID 42163764›Full record

ReviewMini reviews in medicinal chemistry2026

Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma.

Si Qi Yi, Lu Lu Chen, Li Xv, Qin Jiao Fu, Yan Zhu Liu, YingYing Zhang, Meng Xian Jia, Xiang Min Tong, Ying Wang, Juan Qing Yue

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Si Qi YiSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Lu Lu ChenSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Li XvSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Qin Jiao FuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Yan Zhu LiuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
YingYing ZhangSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
Meng Xian JiaDepartment of Orthopedics (Spine Surgery), the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiang Min TongHangzhou First People's Hospital, Affiliated Westlake University, Hangzhou, Zhejiang, 310006, China.
Ying WangSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Juan Qing YueHangzhou First People's Hospital, Affiliated Westlake University, Hangzhou, Zhejiang, 310006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has made significant progress in treating hematologic tumors, particularly diffuse large B-cell lymphoma (DLBCL). However, over 50% of patients are resistant after CAR-T cell therapy for DLBCL, and drug resistance is gradually becoming a major obstacle limiting its efficacy. This review primarily focuses on the mechanisms of resistance to CAR-T cell therapies, including immune escape of tumor cells, CAR-T cell dysfunction, and the tumor microenvironment (TME). It explores potential predictive markers of resistance in the context of relevant resistance mechanisms, such as tumor cell surface antigens, CAR-T cell function, and gene mutation-related substances within the tumor microenvironment. The exploration of these potential predictive markers yields some relevant insights for future studies on resistance to CAR-T in the treatment of DLBCL.

Indexed as

Biomarkers, TumorDrug Resistance, NeoplasmImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenAnimalsHumansTumor MicroenvironmentBiomarkers, TumorReceptors, Chimeric AntigenbiomarkersCAR-Tcell therapydiffuse large B-cell lymphomadoxorubicindrug resistance

Identifiers

PMID42163764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.